Literature DB >> 31262589

Defining the multiplicity and time of infection for the production of Zaire Ebola virus-like particles in the insect cell-baculovirus expression system.

Ana Ruth Pastor1, Gonzalo González-Domínguez2, Marco A Díaz-Salinas3, Octavio T Ramírez4, Laura A Palomares5.   

Abstract

The Ebola virus disease is a public health challenge. To date, the only available treatments are medical support or the emergency administration of experimental drugs. The absence of licensed vaccines against Ebola virus impedes the prevention of infection. Vaccines based on recombinant virus-like particles (VLP) are a promising alternative. The Zaire Ebola virus serotype (ZEBOV) is the most aggressive with the highest mortality rates. Production of ZEBOV-VLP has been accomplished in mammalian and insect cells by the recombinant coexpression of three structural proteins, the glycoprotein (GP), the matrix structural protein VP40, and the nucleocapsid protein (NP). However, specific conditions to manipulate protein concentrations and improve assembly into VLP have not been determined to date. Here, we used a design of experiments (DoE) approach to determine the best MOI and TOI for three recombinant baculoviruses: bac-GP, bac-VP40 and bac-NP, each coding for one of the main structural proteins of ZEBOV. We identified two conditions where the simultaneous expression of the three recombinant proteins was observed. Interestingly, a temporal and stoichiometric interplay between the three structural proteins was observed. VP40 was required for the correct assembly of ZEBOV-VLP. High NP concentrations reduced the accumulation of GP, which has been reported to be necessary for inducing a protective immune response. Electron microscopy showed that the ZEBOV-VLP produced were morphologically similar to the native virus micrographs previously reported in the literature. A strategy for producing ZEBOV in insect cells, which consists in using a high MOI of bac-VP40 and bac-GP, and reducing expression of NP, either by delaying infection or reducing the MOI of bac-NP, was the most adequate for the production of VLP.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Design of experiments; Ebola virus disease; Virus-like particles; ZEBOV-VLP

Year:  2019        PMID: 31262589     DOI: 10.1016/j.vaccine.2019.06.029

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

Review 1.  Innovations in the Insect Cell Expression System for Industrial Recombinant Vaccine Antigen Production.

Authors:  Manon M J Cox
Journal:  Vaccines (Basel)       Date:  2021-12-20

2.  Integrating nanoparticle quantification and statistical design of experiments for efficient HIV-1 virus-like particle production in High Five cells.

Authors:  Eduard Puente-Massaguer; Martí Lecina; Francesc Gòdia
Journal:  Appl Microbiol Biotechnol       Date:  2020-01-06       Impact factor: 4.813

3.  A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.

Authors:  Fangfang Wu; Shengnan Zhang; Ying Zhang; Ruo Mo; Feihu Yan; Hualei Wang; Gary Wong; Hang Chi; Tiecheng Wang; Na Feng; Yuwei Gao; Xianzhu Xia; Yongkun Zhao; Songtao Yang
Journal:  Viruses       Date:  2020-01-03       Impact factor: 5.048

Review 4.  Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases.

Authors:  Hasnat Tariq; Sannia Batool; Saaim Asif; Mohammad Ali; Bilal Haider Abbasi
Journal:  Front Microbiol       Date:  2022-01-03       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.